These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11025 related articles for article (PubMed ID: 15603188)

  • 21. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
    Kudo-Saito C; Schlom J; Hodge JW
    Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.
    Jäger E; Karbach J; Gnjatic S; Neumann A; Bender A; Valmori D; Ayyoub M; Ritter E; Ritter G; Jäger D; Panicali D; Hoffman E; Pan L; Oettgen H; Old LJ; Knuth A
    Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14453-8. PubMed ID: 16984998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
    Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
    J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage.
    Yu Q; Jones B; Hu N; Chang H; Ahmad S; Liu J; Parrington M; Ostrowski M
    Vaccine; 2006 Sep; 24(40-41):6376-91. PubMed ID: 16859816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alphavirus-based vaccines.
    Lundstrom K
    Curr Opin Mol Ther; 2002 Feb; 4(1):28-34. PubMed ID: 11883692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Canarypox and fowlpox viruses as recombinant vaccine vectors: an ultrastructural comparative analysis.
    Pacchioni S; Volonté L; Zanotto C; Pozzi E; De Giuli Morghen C; Radaelli A
    Arch Virol; 2010 Jun; 155(6):915-24. PubMed ID: 20379750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-cell immunity generated by recombinant adenovirus vaccines.
    Yang TC; Millar JB; Grinshtein N; Bassett J; Finn J; Bramson JL
    Expert Rev Vaccines; 2007 Jun; 6(3):347-56. PubMed ID: 17542750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination.
    Minke JM; Fischer L; Baudu P; Guigal PM; Sindle T; Mumford JA; Audonnet JC
    Vet Immunol Immunopathol; 2006 May; 111(1-2):47-57. PubMed ID: 16580075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus.
    Guthrie AJ; Quan M; Lourens CW; Audonnet JC; Minke JM; Yao J; He L; Nordgren R; Gardner IA; Maclachlan NJ
    Vaccine; 2009 Jul; 27(33):4434-8. PubMed ID: 19490959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
    Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical development of MVA-based therapeutic cancer vaccines.
    Acres B; Bonnefoy JY
    Expert Rev Vaccines; 2008 Sep; 7(7):889-93. PubMed ID: 18767940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs.
    Kyriakis CS; De Vleeschauwer A; Barbé F; Bublot M; Van Reeth K
    Vaccine; 2009 Apr; 27(16):2258-64. PubMed ID: 19428840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
    Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
    Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope.
    Kazaks A; Balmaks R; Voronkova T; Ose V; Pumpens P
    Biotechnol J; 2008 Nov; 3(11):1429-36. PubMed ID: 18956370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant DNA virus vectors for vaccination.
    Moss B
    Semin Immunol; 1990 Sep; 2(5):317-27. PubMed ID: 2134016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Virus-like particles: a new family of delivery systems.
    Boisgérault F; Morón G; Leclerc C
    Expert Rev Vaccines; 2002 Jun; 1(1):101-9. PubMed ID: 12908517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mimotope vaccines for cancer immunotherapy.
    Sharav T; Wiesmüller KH; Walden P
    Vaccine; 2007 Apr; 25(16):3032-7. PubMed ID: 17276556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
    Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 552.